Waters (WAT) and Solta Medical (SLTM) Head to Head Analysis

Waters (NYSE: WAT) and Solta Medical (NASDAQ:SLTM) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

92.1% of Waters shares are owned by institutional investors. 5.1% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Waters and Solta Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Waters 24.34% 23.61% 11.84%
Solta Medical N/A N/A N/A

Valuation and Earnings

This table compares Waters and Solta Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Waters $2.17 billion 7.42 $521.50 million $6.78 29.83
Solta Medical N/A N/A N/A $0.02 N/A

Waters has higher revenue and earnings than Solta Medical. Solta Medical is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Waters and Solta Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters 0 10 5 0 2.33
Solta Medical 0 0 0 0 N/A

Waters presently has a consensus price target of $195.29, suggesting a potential downside of 3.43%.

Summary

Waters beats Solta Medical on 8 of the 8 factors compared between the two stocks.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company’s instruments, as well as other suppliers’ instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.

Solta Medical Company Profile

Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company’s systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company’s portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation. The Thermage system provides non-invasive skin tightening and the Liposonix system provides non-invasive body contouring. Isolaz and CLARO provide options to resolve acne. In January 2014, Valeant Pharmaceuticals International Inc ‘s wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply